optos plc (OPTS:London)
optos plc (OPTS) Snapshot
|
Open
123.25 GBp
|
Previous Close
122.25 GBp
|
|
|
Day High
129.75 GBp
|
Day Low
123.25 GBp
|
|
|
52 Week High
10/22/12 - 228.25 GBp
|
52 Week Low
05/16/13 - 110.25 GBp
|
|
|
Market Cap
92.3M
|
Average Volume 10 Days
169.9K
|
|
|
EPS TTM
0.20 GBp
|
Shares Outstanding
72.1M
|
|
|
EX-Date
--
|
P/E TM
9.5x
|
|
|
Dividend
--
|
Dividend Yield
--
|
optos plc (OPTS) Related Businessweek News
No Related Businessweek News Foundoptos plc (OPTS) Details
Optos plc, a retinal imaging company, provides diagnostic and treatment devices for eyecare to healthcare professionals in North America and internationally. The company’s medical devices produce ultra-widefield, high resolution digital images of approximately 82% of the retina, which provide clinical information by facilitating the early detection, management, and treatment of disorders and diseases evidenced in the retina, such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. Its retinal devices are also used for the treatment of non-eye diseases, such as diabetes, hypertension, cardiovascular disease, and cancers. The company's ultra-widefield imaging devices include the P200 and 200Dx devices and the Daytona, which are concentrated on wellness screening carried out in primary care; the P200C devices that are designed to serve the need for clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices; and the P200MA and 200Tx devices, which support the medical care market. It also offers optical coherence tomography (OCT) imaging products, such as Optos OCT SLO system, which combines spectral OCT imaging with a confocal scanning laser ophthalmoscope in an instrument that allows clinicians to diagnose and track changes in the retinal diseases and their treatments; and AC Cornea Lens, which provides high-resolution spectral OCT imaging of the cornea and angle. In addition, the company provides OCT diagnostic devices and optical ultrasound scanners that are used in the diagnosis and management of eye disease and conditions, as well as develops image management software. Optos plc provides its products directly, as well as through distributors to optometrists, ophthalmologists, and vitreo-retinal specialists. The company was founded in 1992 and is headquartered in Dunfermline, the United Kingdom.
optos plc (OPTS) Top Compensated Officers
optos plc (OPTS) Key Developments
Optos plc reported unaudited consolidated earnings results for the first half year ended March 31, 2013. For the period, the company reported revenue of $72.2 million compared to $86.2 million a year ago. Operating loss was $0.6 million compared to operating profit of $5.5 million a year ago. Profit before taxation was $0.7 million compared to $5.6 million a year ago. Net profit for the period attributable to equity holders of the parent was $0.4 million compared to $3.5 million a year ago. Diluted profit before taxation per ordinary share was 1.0 cents compared to 7.5 cents a year ago. Diluted profit after taxation per ordinary share was 0.5 cents compared to 4.6 cents a year ago. Net cash flows used in operating activities was $20.1 million compared to net cash flows from operating activities of $2.3 million a year ago. Purchases of property, plant and equipment was $1.1 million compared to $6.6 million a year ago. Expenditure on intangible assets was $1.0 million compared to $3.7 million a year ago. Net debt (cash less debt & lease finance liabilities) as on March 31, 2013 was $55.8 million compared to $48.2 million as of March 31, 2012. Guidance for the full year is that top line revenue will be lower than fiscal 2012. As normally occurs, the company expects that second half sales will exceed first half, especially given the second OPSM order which has already been secured. The company expects to place about 1,000- 1,200 units of Daytona in the year. Cost control will be maintained, with savings from the new organization structure driving further cost reductions in fiscal 2014. Operating profit will also be below 2012 and net debt will remain above the level at September 30, 2012.
Optos plc, H1 2013 Earnings Call, May 16, 2013
Optos plc announced that the results from a study comparing retinal imaging techniques in 339 eyes conducted at the New England College of Optometry were published in Eye and Brain. The purpose of this study was to evaluate the ability of an optomap-assisted fundus examination to detect retinal lesions in comparison with traditional ophthalmoscopy. Researchers investigated whether Optos' ultra-widefield retinal imaging technology could enable a more comprehensive exam; the accuracy of current traditional dilated retinal exams has been reported in literature to vary from 32% to 82%. The traditional dilated eye exam consisted of Binocular Indirect Ophthalmoscopy (BIO) and slit lamp biomicroscopy with condensing lenses. The image-assisted method was identical to the traditional method, with the exception that the doctor reviewed optomap(R) images in conjunction with ophthalmoscopy. A Retinal Specialist examined patients when there was disagreement in the findings of the two methods.
| Recently Viewed | |||
| OPTS:LN | 128.00 GBp | +5.75 | |
| Company | Last | Change | |
| No competitor information is available for OPTS. | |||
| View Industry Companies | |||
Industry Analysis
OPTS
Industry Average
| Valuation | OPTS | Industry Range |
| Price/Earnings | 7.8x |
|
| Price/Sales | 0.7x |
|
| Price/Book | 1.1x |
|
| Price/Cash Flow | 7.6x |
|
| TEV/Sales | 0.7x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Thornton, CO | IntuitPosted: Apr 29
Sponsored Financial Commentaries
Sponsored Links
To contact OPTOS PLC, please visit www.optos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








